Every 10-Q that Bio-Techne Corp (TECH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TECH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TECH filings page.
Bio-Techne Corporation reported net sales of $311.4 million for the quarter ended March 31, 2026, down 2% from a year earlier, as softer Protein Sciences demand outweighed growth in Diagnostics and Spatial Biology. Organic revenue declined 2%, with foreign currency adding 2% and the absence of a held-for-sale business subtracting 2%.
Despite lower sales, GAAP net earnings rose to $51.0 million from $22.6 million, helped by a sharp reduction in litigation charges and ongoing cost management. Diluted EPS was $0.32, up from $0.14. Reported gross margin was 66.9%, slightly below last year as product mix shifted, and adjusted gross margin was 70.4%.
Operating cash flow for the nine months reached $196.7 million, up from $189.4 million, supporting higher cash and cash equivalents of $209.8 million and enabling $146.0 million of debt repayment, reducing long-term debt to $200.0 million. Segment operating margins remained strong at 44.2% for Protein Sciences and improved to 12.1% for Diagnostics and Spatial Biology, reflecting restructuring benefits and the Exosome Diagnostics divestiture.
Bio‑Techne reported essentially flat revenue but stronger profits for the quarter ended December 31, 2025. Net sales were $295.9 million versus $297.0 million a year earlier, while net earnings rose to $38.0 million from $34.9 million. Diluted EPS increased to $0.24 from $0.22.
GAAP gross margin slipped to 64.6% from 65.3%, and adjusted gross margin fell to 68.5% from 70.5%, mainly from product mix. Selling, general and administrative expenses declined 6% to $113.7 million as cost management and restructuring took hold.
The Protein Sciences segment grew sales 2% to $215.1 million but saw lower margins, while Diagnostics and Spatial Biology reported a 4% sales decline to $81.2 million but a much stronger 10.4% operating margin, helped by the Exosome Diagnostics divestiture and efficiency initiatives. Operating cash flow was $110.0 million for the six months, and debt under the credit facility fell to $260.0 million.
Bio‑Techne (TECH) reported Q1 FY2026 results. Net sales were $286.6 million versus $289.5 million a year ago as Protein Sciences softened while Diagnostics & Spatial Biology improved organically. Gross margin rose to 65.6% from 63.2%, and operating income increased to $47.7 million from $40.0 million. Net earnings were $38.2 million with diluted EPS of $0.24, up from $0.21.
Cash flow from operations was $27.6 million. Cash and equivalents were $145.0 million, and long‑term debt decreased to $300.0 million from $346.0 million, reflecting $46.0 million in repayments. Segment detail: Protein Sciences sales were $202.2 million (down 1%), operating margin 38.4%; Diagnostics & Spatial Biology sales were $79.5 million (down 4% reported; organic growth 3%), operating margin 11.2% versus 5.1%. The quarter included a $6.8 million recovery related to the Exosome Diagnostics divestiture and receipt of MDxHealth stock valued at $8.7 million. EMEA (ex‑UK) grew, while the United States declined year over year.